Sildenafil citrate improves the delivery and anticancer activity of doxorubicin formulations in a mouse model of breast cancer

• Published in: Journal of drug targeting Vol. 26; no. 7; p. 610
• Main Authors: Greish, Khaled, Fateel, Maryam, Abdelghany, Sara, Rachel, Nanitha, Alimoradi, Houman, Bakhiet, Moiz, Alsaie, Ahmed
• Format: Journal Article
• Language: English
• Published: England 01.08.2018
• Subjects: Sildenafil citrate; micelle; anticancer activity; drug delivery
• ISSN: 1029-2330
• DOI: 10.1080/1061186X.2017.1405427

Sildenafil is an approved drug for the treatment of erectile dysfunction. The drug exerts its action through the relaxation of smooth muscles and the modulation of vascular endothelial permeability. In this work, we tested whether the aforementioned effects of sildenafil on tumour vasculatures could result in an improvement of anticancer drug concentration in tumour tissues and hence improves its anticancer effect. Sildenafil when added to doxorubicin showed synergistic anticancer activity against 4T1 breast cancer cells in vitro. Adding 1, 30 and 100 μM of Viagra to 1 μM of doxorubicin resulted in 1.8-fold, 6.2-fold and 21-fold statistically significant increases in its cytotoxic effect, respectively. As a result, 4T1 tumour-bearing mice showed up to 2.7-fold increase in drug concentrations of the fluorescent Dye DiI and doxorubicin in tumour tissues, as well as their nanoformulations. Animals treated with the combinations of both Sildenafil citrate and doxorubicin showed a statistically significant 4.7-fold reduction in tumour size compared to doxorubicin alone. This work highlights the effect of Sildenafil on tumour vasculatures and provides a rational for further testing the combination on breast cancer patients.